Personal Cancer Assessment

Appears in the April 2021 issue.

Tempus, a Chicago-based med tech company, has developed a new test that will help oncologists diagnose and treat hereditary cancers. xG is a 52-gene panel that identifies genetic mutations associated with cancer syndromes and inherited risk of cancer. “The full molecular assessment gives insight to why patients developed cancer to begin with,” says chief medical officer Kim Blackwell. “Clinicians can better diagnose and treat their patients when aware of existing hereditary mutations.”

Photo courtesy Tempus